{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014618","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.940176+00:00","generated_at":"2026-05-22T11:57:36.523525+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston","bullets":["Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.","Previous positive preclinical data (Oct 2024) showed Reqorsa reduced GBM cell viability and suppressed migration.","TUSC2 tumor suppressor identified as novel target for glioblastoma by UTHealth Houston researchers.","Company believes results support further in vivo evaluation in malignant glioma mouse models."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014618","json":"https://secwatch.observer/filing/0001437749-25-014618.json","markdown":"https://secwatch.observer/filing/0001437749-25-014618.md","text":"https://secwatch.observer/filing/0001437749-25-014618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/0001437749-25-014618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/gnpx20250428_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:57:36.523525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}